59 related articles for article (PubMed ID: 30872780)
1. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
2. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
[TBL] [Abstract][Full Text] [Related]
3. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
4. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
[TBL] [Abstract][Full Text] [Related]
6. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
Karademir D; Özgür A
Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
Choi J; Ceribelli M; Phelan JD; Häupl B; Huang DW; Wright GW; Hsiao T; Morris V; Ciccarese F; Wang B; Corcoran S; Scheich S; Yu X; Xu W; Yang Y; Zhao H; Zhou J; Zhang G; Muppidi J; Inghirami GG; Oellerich T; Wilson WH; Thomas CJ; Staudt LM
Cancer Cell; 2024 May; 42(5):833-849.e12. PubMed ID: 38701792
[TBL] [Abstract][Full Text] [Related]
8. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
[TBL] [Abstract][Full Text] [Related]
9. YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma.
Shan H; Cao Y; Xiao X; Liu M; Wu Y; Zhu Q; Xu H; Lei H; Yao Z; Wu Y
Signal Transduct Target Ther; 2020 Jul; 5(1):116. PubMed ID: 32632092
[No Abstract] [Full Text] [Related]
10. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
[TBL] [Abstract][Full Text] [Related]
11. Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044.
Cheng C; Wang T; Song Z; Peng L; Gao M; Hermine O; Rousseaux S; Khochbin S; Mi JQ; Wang J
Cancer Med; 2018 Feb; 7(2):380-396. PubMed ID: 29277967
[TBL] [Abstract][Full Text] [Related]
12. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation.
Liu P; Zhao L; Zitvogel L; Kepp O; Kroemer G
Cell Death Differ; 2023 Dec; 30(12):2447-2451. PubMed ID: 37845384
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma.
Plotnik JP; Richardson AE; Yang H; Rojas E; Bontcheva V; Dowell C; Parsons S; Wilson A; Ravanmehr V; Will C; Jung P; Zhu H; Partha SK; Panchal SC; Mali RS; Kohlhapp FJ; McClure RA; Ramathal CY; George MD; Jhala M; Elsen NL; Qiu W; Judge RA; Pan C; Mastracchio A; Henderson J; Meulbroek JA; Green MR; Pappano WN
Mol Cancer Ther; 2024 Mar; ():. PubMed ID: 38507740
[TBL] [Abstract][Full Text] [Related]
14. Risk/benefit of BTK/venetoclax combos: the context matters!
Seymour JF
Blood; 2024 Feb; 143(7):563-564. PubMed ID: 38358849
[No Abstract] [Full Text] [Related]
15. Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.
Efremov DG; Turkalj S; Laurenti L
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32481736
[TBL] [Abstract][Full Text] [Related]
16. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
17. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H; Stephenson RE; Reynolds R; Shah S; Puri R; Butler SD; Trujillo-Alonso V; Teater MR; van Besien H; Gibbs-Curtis D; Ueno H; Parvin S; Letai A; Mathew S; Singh A; Cesarman E; Melnick A; Giulino-Roth L
Blood Adv; 2020 Oct; 4(20):5226-5231. PubMed ID: 33104794
[TBL] [Abstract][Full Text] [Related]
18. BR vs. R‑miniCHOP in unfit patients with B‑cell non‑Hodgkin lymphoma: A randomized, two‑center, cohort study.
Zhang D; Lin Y; Dong Y; Zhang L
Oncol Lett; 2023 Oct; 26(4):440. PubMed ID: 37664664
[TBL] [Abstract][Full Text] [Related]
19. Apatinib enhances chemosensitivity of ABT-199 in diffuse large B-cell lymphoma.
Shi Y; Ye J; Shen H; Xu Y; Wan R; Ye X; Jin J; Xie W
Mol Oncol; 2022 Oct; 16(20):3735-3753. PubMed ID: 36053810
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]